Article
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Cancer - 15 Jul 2014
Alvarado Yesid, Kantarjian Hagop M, Luthra Rajyalakshmi, Ravandi Farhad, Borthakur Gautam, Garcia-Manero Guillermo, Konopleva Marina, Estrov Zeev, Andreeff Michael, Cortes Jorge E
Abstract excerpt
BACKGROUND: FLT3-internal tandem duplication (ITD) mutations are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have shown clinical activity in AML with FLT3-ITD, but responses are usually short-lived. METHODS: This study examined 69 FLT3-mutated patients with AML, who were treated with different FLT3 inhibitors to analyze emergence of new mutations. RESULTS: At...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.